SUMMARY The effect of acebutolol (1 mg/kg i.v. during the first 2 days followed by a daily oral dose of 600 mg for 3 weeks) was studied in a randomized trial involving 26 patients seen within 24 hours after the onset of uncomplicated anterior transmural myocardial infarction (TMI). Myocardial ischemia and necrosis were evaluated by precordial maps recorded daily for 9 days. Left ventricular pump function and dyssynergy were quantitatively measured on 300 right anterior oblique cineangiograms. Angiography was performed, using the postextrasystolic potentiation technique, within the first 24 hours after TMI and was repeated 1 month later. The basal and postextrasystolic beats from the initial angiography were computerized and compared wih those from the final angiogram. MB-CK serum level was measured from blood samples drawn every 3 hours for the first 72 hours.
BENEFICIAL EFFECTS from ,3-blockade therapy have been demonstrated in experimental coronary artery occlusions'-' and clinical acute myocardial infarction (MI).' Several studies have suggested that the delay in instituting adrenergic blockade is critical for limiting infarct size; reduction of myocardial infarct size can be expected only when therapy is begun within 4-6 hours after the onset of experimental2' 3 or clinical7-9 acute coronary occlusion. However, not all patients can reach a coronary care unit that soon after MI. Further, extension of necrosis occurs in more than half of them within the first few days after the onset of symptoms.'0-7 Thus, the question arises whether /3-blocking therapy can prevent or reduce the incidence of infarct extension when it is initiated at 6-24 hours after MI.
Previous studies have suggested that ST and QRS changes are valuable indicators of myocardial ischemia and necrosis.' 4 6. 11-14. 3 Hence, serial observations of precordial ST and QRS mapping for several days afer onset should detect extension in the early stages of MI. But the efficacy of interventions designed to prevent infarct extension and then limit final infarct size should be ultimately' assessed only from quantitative measurements of objective indexes of myocardial function. In this regard, regional wall motion abnormalities estimated from left ventricular (LV) cineangiograms have been identified as a sensitive and specific index of myocardial ischemia or necrosis. 3539 An investigation in our laboratory40 showed the ability of postextrasystolic potentiation (PESP) to predict reversible wall motion abnormalities from contrast ventriculograms in untreated patients with acute transmural myocardial infarction (TMI).
A few studies of infarct size limitation7 9 have used a randomization procedure. In these studies, precordial mapping has not been done, angiography has failed to show significant improvement from 13-blocking therapy,9 and the efficacy of propranolol has been assessed only from enzyme measurements in patients treated within 4 hours after the onset of symptoms. The present randomized clinical trial was designed to determine the effects of an established 18-blocking drug (acebutolol) given within the 24 hours after acute anterior TMI in patients without signs of cardiac failure. Infarct extension was detected by mapping and by enzyme measurements. Myocardial function was assessed by angiography during PESP on the first day and by comparing the initial angiographic data with those obtained 1 month later.
Methods

Selection of Patients
All patients selected for study had an acute anterior TMI less than 24 hours after the onset of pain, as documented by serial 12-lead ECGs and characteristic elevations in serum enzymes (CK and MB-CK). Patients 70 years and older and those with previous in-986 farctions, associated cardiovascular or systemic disease, mechanical complication, persistent or recurrent ischemic pain not relieved by opiates and nitroglycerin afer 12 hours, clinical signs of coronary insufficiency present more than 3 months before the current TMI, atrioventricular or intraventricular conduction disturbances, or refractory arrhythmias were excluded from the study. Patients taking chronic drug therapy (such as ,/-blocking agents, digitalis, lidocaine or other antiarrhythmic drugs) were also excluded. All patients who met the selection criteria were in Killip class 141 and in sinus rhythm.
These selection criteria were carefully controlled for each patient so we could study a homogeneous sample of untreated subjects without previous cardiovascular problems within 24 hours after a first anterior TMI not complicated by clinical pump failure or persistent chest pain.
All the patients selected underwent cardiac catheterization for further hemodynamic selection. Right-heart pressure, capillary wedge pressure (CWP), femoral arterial pressure, and thermodilution cardiac output (Edwards 9520) were measured. When CWP was 15 mm Hg or more, or when cardiac index was 2.5 1/min/ m2 or less, the patient was rejected from the study. As a result, four patients who were in Killip class I were excluded. Twenty-six patients fulfilled all selection criteria.
Randomization Procedures
The 26 patients were assigned at random to one of two groups. Group A included 12 patients, ages 29-61 years (mean 52 years), who received only heparin during their 1-month hospitalization and served as controls. Group B included 14 patients, ages 31-63 years (mean 51 years), who, in addition to heparin, received acebutolol immediately after the initial measurements and in all the cases within 24 hours. Acebutolol was infused intravenously at a rate of 1 mg/kg body weight for 48 hours, and heart rate, arterial pressure and CWP were monitored continuously. Thereafter, a daily oral dose of 600 mg was given for 3 weeks. Cardiac dynamics studied by PESP in the 12 control patients have been reported in detail. 40 
Protocol
All patients underwent electrocardiographic, enzymatic, and angiographic evaluation 6-24 hours after the onset of chest pain. Pulmonary angiography was first performed in the 300 right anterior oblique (RAO) position42 immediately after the hemodynamic measurements while a right ventricular stimulus was delivered at 50% of the RR interval through a bipolar pacing catheter to obtain PESP, as described previously. 40 The initial mapping was done immediately after catheterization (mean 15 hours, range 11-21 hours). With the patient supine, precordial maps were recorded from a grid of 42 
Results
Comparison of Initial Data Values
Initial data recorded in the control group and in the treated patients are listed in tables 1 and 2. There were no significant differences between groups for any variable or set of variables on the first day of the study. However, the coronary angiograms showed that group B patients had significantly worse peripheral runoff and collateral flow than the control group. The number, the degree, and the localization of luminal occlusions were similar in the two groups. Therefore, the groups were considered comparable and suitable for evaluation of /3-blocking drug efficacy.
Comparison of Initial and Final Data Values
The most meaningful evolutionary changes observed are summarized in tables 1 and 2. There was no Figures 1 and 3 show the mean evolutionary changes of NST, EST, NQ, and XQ in both groups. During the 9-day observation period, the groups remained comparable. All the variations between paired measurements of each variable 1-8 days apart were examined. These comparisons showed no significant difference between groups. Indeed, there was a larger increase of NST and XST mean differences in group B than in group A from the beginning to the end of the observation period (table 3) . But the variances were so high that no significance level was attained at any time. The highest degree of variability for NST paired measurements occurred at day 4 for both groups. Fourteen of the 26 patients had an infarct extension: six in group A and nine in group B (fig. 4) . The number of NST augmentations and the maximal peak increase were not significantly different between the two groups. However, the NST augmentations in group B were significantly delayed (mean 6.4 ± 1.6 days; range 3-8 days) compared with those in group A (mean 3.2 + 1.2 days; range 2-5 days) (p < 0.01). Though LV angiography assesses wall motion abnormalities of the left ventricle only, various studies have suggested that angiographic data correlate well with indexes of necrosis obtained from precordial mapping5456 and also with enzymatic estimates of infarct size.36-39 We used both precordial mapping and LV angiography in the present trial.
We considered several points in attempting to assess myocardial ischemic injury from precordial mapping. First, the delay of the initial record from the onset of the infarct may be critical. The initial map was performed 11-24 hours after the onset of pain, while the ST segment was relatively stable, as documented by previous reports. 16 22, 28, 34, 53, 57, 58 Thus, comparisons with subsequent records could be made with baseline measurements taken during a relatively stable period. Second, because of the 24-hour interval between daily maps, transient ST-segment elevations may have been undetected. However, Thompson and Katavatis50 showed that when ST-segment elevation accompanies significant myocardial necrosis, it persists long enough to be detected within 24 hours. Third, nonspecific changes in precordial ST-segment elevation, such as fluctuations in serum potassium levels or the development of pericarditis, may occur and alter the relationship of the ST segment to ischemic injury. As STsegment changes alone are unreliable detectors of ischemia, infarct extension was diagnosed only when NST increased by more than 20% and IQ increased by more than 10% between two consecutive days and there was significant further release of MB-CK.
The aim of the present study was to detect infarct extensions and to determine whether the incidence and magnitude of extensions were reduced by acebutolol and whether indexes of necrosis at 9 days and cardiac 61 and the present study (table 2) . The cineangiographic data also showed a high variability and an' increase of variances on day 30 compared with day 1 (table 1). In a previous work,40 ejection fraction, hypokinesis and akinesis recorded on day 1 correlated poorly with those on day 30. In contrast, correlations increased markedly as the final angiograms were compared with the electrically induced postextrasystolic initial beat. In the present study, the same pattern of predictability based on the initial postextrasystolic cardiac cycle was found in both groups, though there was more scatter of values in the group B than in the control group ( fig. 2) . If a beneficial effect of the ,8-blocking therapy is to be expected, the final values in group B patients should be greater for ejection fraction and lower for hypokinesis and akinesis than those predicted from the postextrasystolic cycle of the initial angiography when no drug had been given. Although more favorable trends can be observed in group B (fig. 2, table 1 ), our results fail to confirm the beneficial effects of the 18-blocking drug statistically.
The large variances of the measured variables might have helped circumvent any significant improvement in LV function. Norris et al. 9 showed that propranolol failed to improve cardiac dynamics in similar-sized samples, but they did not study predictability of final regional wall motion abnormalities using PESP in the initial course of MI.
Finally, by taking into account the number of patients and the variances, we computed the theoretical differences required to attain the 5% probability level for unilateral tests (table 4) . Differences needed to significantly prove the efficacy of 13-blocking therapy using the same samples should have reached 12-17% for ejection fraction, hypokinesis and akinesis, compared with the 3-6% observed differences. Thus, one must ask whether sufficient benefit from 13-blocker therapy during the first 24 hours of TMI is to be expected, taking into account the possibility of worsening pump function by depression of contractility. We found four patients who were in Killip class I but had hemodynamic signs of cardiac failure and therefore were excluded from our study. Hence, i.v. 13-blocking agents should not be systematically given in the first 24 hours without hemodynamic monitoring in the coronary care unit. We are not certain that a significant improvement of the overall or regional LV function can be expected. 
